Blue print medicine stock7/23/2023 ![]() Previous to Biodesix, Wendy served as VP of Sales with Integrated Oncology, and her responsibilities included successfully integrating US Labs and Genzyme Genetics under one umbrella. Prior to that, Wendy served as CCO with Biodesix, where she relaunched VeriStrat and brought the GeneStrat test to market, both of which resulted in continuous record growth. Most recently, Wendy served as CCO for Animated Dynamics, an imaging company that delivers drug assessments in 3D living tissue samples. Wendy’s career history includes working at Animated Dynamics, Strand Diagnostics, Biodesix, Integrated Oncology, and Cytyc Corporation. ![]() She also comes with extensive experience in marketing, corporate advocacy and sales training. Wendy joined Agendia in May 2019 and brings 20 years of success in launching, relaunching and leading commercial organizations in diagnostic, surgical and capital sales, with a focus in Oncology and Women’s Health. His earlier career spanned scientific cancer research at the Dana Farber Cancer Institute and Human Genome Project.Ī biochemist and economist by training, Roopom has a graduate degree from Harvard and two undergrad degrees from MIT where he was elected a Howard Hughes Medical Institute Scholar. Previously, Roopom led teams at McKinsey, Leerink and Goldman Sachs where he completed 80+ healthcare transactions raising over $10Bn in capital financings, 30+ IPOs, and 20+ M&A transactions. Most recently, he was President and CEO of RainDance Technologies (acquired by BioRad Labs) and led the company to become a pioneer in Liquid Biopsy for detecting cancer from a blood test. He has broad experience with startups to global Fortune 500 companies advising on corporate strategy, portfolio design, product development and commercialization, financing, partnerships and acquisitions. Roopom is a life science business leader with 20 years’ experience covering strategy, financial advisory, operational and scientific roles. van ‘t Veer with a European Inventor Award.ĬHIEF STRATEGY OFFICER AND HEAD OF BUSINESS DEVELOPMENT In 2015, the European Patent Office (EPO) recognized MammaPrint’s impact on breast cancer diagnostics by honoring Dr. She was awarded a 2014 European Union Prize for Women Innovators that acknowledges the ways MammaPrint has helped transform breast cancer care. She is also the former head of the NKI’s DNA-diagnostic laboratory. van ‘t Veer was appointed Professor of Laboratory Medicine and Director of Applied Genomics at the University of California San Francisco. After patenting their innovation, she and research partner René Bernards founded Agendia and launched the MammaPrint test. They established that a specific DNA signature made up of 70 genes distinguished whether breast cancer tumors had a low or high risk of recurrence. van ‘t Veer is best known for work stemming from a discovery she and her team made at the Netherlands Cancer Institute (NKI). She has a 20-year track record in molecular oncology research, which includes more than 230 scientific publications and prestigious awards for her contributions to breast cancer care.ĭr. As one of the world’s leading innovators in cancer diagnostics, she is widely recognized as a pioneer in the field of personalized medicine, also known as precision medicine. Laura van ‘t Veer, PhD, is co‑founder of Agendia and serves as its Chief Research Officer. CHIEF RESEARCH OFFICER (CRO) AND CO‑FOUNDER
0 Comments
Leave a Reply. |